Muhammed Oumer Sada, Nasir Beshir Bedru
Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Drug Healthc Patient Saf. 2020 Sep 10;12:161-168. doi: 10.2147/DHPS.S260364. eCollection 2020.
Ceftriaxone is one of the most commonly used antibiotics due to its availability, wide spectrum of activity and low toxicity. However, irrational use of ceftriaxone is one of the current issues in most countries, especially developing ones.
The aim of this study was to evaluate ceftriaxone utilization in different wards of Ras-Desta Memorial General Hospital (RDMGH) in Ethiopia.
An institution-based retrospective cross-sectional study was conducted on randomly selected 1,079 patients who were admitted to RDMGH from May 2017 to April 2018. A structured data abstraction format was used to collect data from patients' medical chart. Micromedex® drug interaction checker was used to identify significant drug-drug interactions, and national and international guidelines were used to evaluate the appropriateness of ceftriaxone use. The data were analyzed by using SPSS version 20.0.
Among the 1,079 patients enrolled, ceftriaxone was utilized by 601 (55.7%) patients, and these patients were considered for evaluation of appropriateness and subsequent analysis. Among 601 patients, ceftriaxone was used for therapeutic purpose in 362 (60.2%) patients; of which, 359 (99.2%) were for empiric therapy and the rest 239 (39.8%) were for prophylaxis. In the majority of the patients, the dose of ceftriaxone was 2g/day 472 (78.6%) and for a duration of 2-7 days 409 (68.1%). Inappropriate use of ceftriaxone was observed among 237 (39.4%) patients with regard to indication, dose/frequency and duration. About half (49.3%) of the deviation from the guidelines was observed from surgical and gynecologic/obstetrics wards. Among the co-prescribed medications with ceftriaxone, ringer lactate, warfarin and heparin were found to have a significant drug-drug interaction.
This study revealed that inappropriate use of ceftriaxone was high in RDMGH. This may increase the emergence of resistant pathogens which may lead to treatment failure and increase cost of therapy. Therefore, adherence to current evidence-based guidelines is recommended.
头孢曲松因其可用性、广泛的活性谱和低毒性,是最常用的抗生素之一。然而,在大多数国家,尤其是发展中国家,不合理使用头孢曲松是当前存在的问题之一。
本研究旨在评估埃塞俄比亚拉斯 - 德斯塔纪念综合医院(RDMGH)不同病房中头孢曲松的使用情况。
对2017年5月至2018年4月期间随机选取的1079例入住RDMGH的患者进行了一项基于机构的回顾性横断面研究。使用结构化数据提取格式从患者病历中收集数据。使用Micromedex®药物相互作用检查器识别显著的药物 - 药物相互作用,并使用国家和国际指南评估头孢曲松使用的适当性。数据使用SPSS 20.0版进行分析。
在纳入的1079例患者中,601例(55.7%)患者使用了头孢曲松,这些患者被纳入适当性评估及后续分析。在601例患者中,362例(60.2%)患者使用头孢曲松用于治疗目的;其中,359例(99.2%)用于经验性治疗,其余239例(39.8%)用于预防。在大多数患者中,头孢曲松的剂量为每日2g,共472例(78.6%),疗程为2 - 7天,共409例(68.1%)。在237例(39.4%)患者中观察到头孢曲松在适应证、剂量/频率和疗程方面存在不当使用情况。约一半(49.3%)的指南偏差出现在外科和妇产科病房。在与头孢曲松联合使用的药物中,发现乳酸林格液、华法林和肝素存在显著的药物 - 药物相互作用。
本研究表明,RDMGH中头孢曲松的不当使用率较高。这可能会增加耐药病原体的出现,导致治疗失败并增加治疗成本。因此,建议遵循当前基于证据的指南。